Mayo Clinic Researchers Examine Unique Injection of Gene Therapy Vectors into Mice’s Kidney
Before gene remedy can be used to deal with renal diseases, the delivery of therapeutic genes to the kidney should become way more efficient. A novel strategy by which three different gene delivery vectors had been injected intravenously and straight into the kidneys of mice was mentioned in an article printed in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert publishers.
Jeffrey Rubin, Tien Nguyen, Kari Allen, and Katayoun Ayasoufi of the Mayo Clinic co-authored the article entitled “Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Related Virus, and Lentiviral Vectors after Intravenous and Direct Kidney Injections.”
As the kidney filters out big compounds from the bloodstream, the researchers decided to study the ability to deliver three different sized vectors through an intravenous route: larger adenovirus vectors (100 nm) lentiviral vectors (120 nm), and small adeno-associated virus vectors (25 nm).
To bypass this refining tool, they also checked two different direct injection routes into the kidney and found these to be better than intravenous injections.
Nevertheless, a number of the vectors had been able to leak out of the kidney, creating the possibility for off-goal tissue effects.
The ability for direct injections opens new possibilities for treating kidney illnesses with gene therapy; however, further enhancements are required.